{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:59:50Z","timestamp":1791050390937,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T00:00:00Z","timestamp":1412035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>Antimicrobial resistance among gram\u2010positive organisms such as methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (<jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content>) and vancomycin\u2010resistant enterococci (<jats:styled-content style=\"fixed-case\">VRE<\/jats:styled-content>) continues to limit therapeutic options. The oxazolidinones are a synthetic class of agents now commonly relied on for the treatment of serious <jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">VRE<\/jats:styled-content> infections. With increasing utilization of linezolid, resistant pathogens have once again begun to emerge. Tedizolid, a next\u2010generation oxazolidinone, possesses a spectrum of activity including <jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">VRE<\/jats:styled-content>, with significantly enhanced potency also against linezolid\u2010resistant strains. Preclinical and early clinical studies have reported positive results, demonstrating a favorable pharmacokinetic profile in combination with key potential safety advantages. In two phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> clinical trials, tedizolid was found noninferior to linezolid in the treatment of acute bacterial skin and skin structure infections. Investigations for treatment of ventilator\u2010acquired and health care\u2013associated pneumonia are currently underway. Tedizolid has been subjected to pharmacodynamics studies throughout its development that have highlighted properties unique to this agent. Considerable accumulations in epithelial lining fluid and antimicrobial activity greatly augmented by the presence of granulocytes suggest that slow but bactericidal activity may be possible in some clinical scenarios. Structural distinctions between tedizolid and linezolid suggest that tedizolid has decreased vulnerability to oxazolidinone resistance mechanisms. Tedizolid minimum inhibitory concentrations are essentially unchanged in organisms possessing the chloramphenicol\u2010florfenicol resistance gene, a horizontally transferable linezolid resistance mechanism. Although the clinical experience with tedizolid remains limited, early data suggest a potential role in the treatment of serious infections due to multidrug\u2010resistant gram\u2010positive pathogens.<\/jats:p>","DOI":"10.1002\/phar.1491","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T06:39:58Z","timestamp":1412059198000},"page":"1198-1208","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Early Experience with Tedizolid: Clinical Efficacy, Pharmacodynamics, and Resistance"],"prefix":"10.1002","volume":"34","author":[{"given":"Jeffrey M.","family":"Rybak","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Kentucky HealthCare Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Kentucky HealthCare Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Kentucky HealthCare Lexington Kentucky"},{"name":"Pharmacy Practice and Science Department University of Kentucky College of Pharmacy Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/491710"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq113"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/650574"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.757"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01569-09"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00171a035"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663-10"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00076-10"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05354-11"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1337"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf066"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/379012"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/381762"},{"key":"e_1_2_6_16_1","unstructured":"HosakoH RadovskyA DraganovDI VijaJ BartizalK.Lack of Neuropathy after Long\u2010Term Tedizolid Administration in Rats. Proceedings of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);Denver CO USA; September 10\u201313 2013."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.1.109.33504"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262339702500401"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-010-0182-1"},{"key":"e_1_2_6_20_1","unstructured":"Pharmaceuticals C. Sivextro (tedizolid phosphate) tablets and injection. FDA Briefing Document Anti\u2010 Infective Drug Advisory Committee Meeting.2014."},{"key":"e_1_2_6_21_1","unstructured":"ProkocimerP BienP MunozKA AsterR.Hematological effects of TR\u2010701 linezolid and placebo administered for 21\u00a0days in healthy subjects. Proceedings of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);Washington DC USA; October 25\u201328 2008."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00431-13"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1784"},{"key":"e_1_2_6_24_1","first-page":"1","article-title":"Antidepressant use in persons aged 12 and over: United States, 2005\u20132008","volume":"76","author":"Pratt LA","year":"2011","journal-title":"NCHS Data Brief"},{"key":"e_1_2_6_25_1","unstructured":"De AndaC FangE DasA ProkocimerP.Integrated Results from Phase 3 Studies Comparing Tedizolid 6 Days vs Linezolid 10 Days in Patients with ABSSSI. Proceedings of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);Denver CO USA; September 10\u201313 2013."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342150-00007"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01565-10"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01303-12"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3484-3489.2002"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00122-12"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1665-1670.2002"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp267"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00502-11"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06121-11"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06427-11"},{"key":"e_1_2_6_37_1","unstructured":"ZurenkoG ToddWM HafkinBA.Development of linezolid\u2010resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. Proceedings of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);San Francisco CA USA; September 26\u201329 1999."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-009-0727-3"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks146"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03842.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","article-title":"In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis","volume":"3","author":"Kaatz GW","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102164\u201012\u2010512"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm246"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01392-13"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00714-10"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2012.03.001"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01886-07"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.051003-0"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.04.002"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt092"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.03.006"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1491","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:16:52Z","timestamp":1761063412000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,30]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/phar.1491"],"URL":"https:\/\/doi.org\/10.1002\/phar.1491","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,30]]},"assertion":[{"value":"2014-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}